Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Clinical trial NCT06279403 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06279403
Sponsor: RenJi Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Clear-cell Metastatic Renal Cell Carcinoma Immune Checkpoint Inhibitors Cytoreductive Nephrectomy

Start date: 2024-03-01
Primary completion: 2026-03-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.